HealthLeaders-InterStudy, a leading provider of managed care industry intelligence, reports that ODS Health Plans enrolled 22,800 Medicare recipients in its Medicare prescription drug product, ODS Advantage Rx, by the end of April. According to the latest issue of Oregon & Washington Health Plan Analysis, this gave it a 17 percent market share, while Humana Insurance and UnitedHealthcare tied with 16 percent shares.

"ODS did have a specific advantage," said Don Mooradian, HealthLeaders-InterStudy analyst. "Oregon Public Employees Retiree Health Insurance Program is their client, and a substantial number of their members enrolled in ODS's PDP.

ODS's PDP plan offered to those outside of the Health Insurance Program carried premiums of $37.40 per month with a $250 deductible and covered 94 of the top 100 drugs in its formulary, according to CMS.

Humana offered three prescription drug plans at $6.93, $12.37 and $51.18 per month. All the plans had formularies that included 99 of the top 100 drugs and only the least expensive had a deductible, which is $250, according to CMS. UnitedHealthcare had two PDPs to offer, one its exclusive arrangement to offer the AARP Medicare Rx Plan. It was $24.89 per month, covered all the top 100 drugs and had no deductible. Its other plan was its own United Medicare MedAdvance for $29.53, also with no deductible and offering all the major drugs.

  Other health plan news in Oregon and Washington:   * Despite a negative ruling in April from the Washington State Court of     Appeals, Premera Blue Cross intends to press its four-year quest to     obtain for-profit status.   * Washington Insurance Commissioner Mike Kreidler wants to try again next     year to regain some regulatory power over individual health insurance     accounts.    About Health Plan Analysis 

Health Plan Analysis identifies key health plan trends, allowing healthcare businesses to create comprehensive strategic plans and sales strategies at state and local levels.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a company of Decision Resources, Inc. (, is the authoritative source for managed care data and analysis. For more information, please visit

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Alex Jablokow   Decision Resources   781-296-2562 

SOURCE: HealthLeaders-InterStudy

CONTACT: Alex Jablokow of Decision Resources, +1-781-296-2562,

First Ever Disease-Modifying Drugs Will Account for Nearly 60% of Market to Treat Alzheimer's Disease In 2015

View Now